Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADV NYSE:MAN NASDAQ:VIE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVAdvantage Solutions$1.30-5.1%$1.44$1.04▼$4.10$444.31M2.07691,060 shs465,599 shsMANManpowerGroup$39.25-4.8%$42.18$37.99▼$75.57$1.91B1.071.11 million shs1.01 million shsVIEViela Bio$53.01$53.01$25.02▼$65.00$2.91B0.431.07 million shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVAdvantage Solutions-5.11%-18.75%-16.13%-5.80%-67.58%MANManpowerGroup-4.84%-14.05%-10.83%-11.23%-48.74%VIEViela Bio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVAdvantage Solutions2.5809 of 5 stars3.51.00.00.02.02.51.3MANManpowerGroup4.4677 of 5 stars2.04.01.73.83.51.72.5VIEViela BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVAdvantage Solutions 3.00Buy$2.2573.08% UpsideMANManpowerGroup 2.00Hold$48.2022.79% UpsideVIEViela Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ADV, SANT, MAN, and VIE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025MANManpowerGroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$42.00 ➝ $45.005/14/2025ADVAdvantage SolutionsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.005/13/2025ADVAdvantage SolutionsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $2.50(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVAdvantage Solutions$3.57B0.12$0.32 per share4.11$2.33 per share0.56MANManpowerGroup$17.54B0.10$6.20 per share6.33$43.11 per share0.91VIEViela Bio$50M58.26N/AN/A$7.14 per share7.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVAdvantage Solutions-$326.96M-$1.16N/AN/AN/A-10.71%-33.99%-8.76%8/7/2025 (Estimated)MANManpowerGroup$145.10M-$0.38N/A6.46N/A-0.09%7.98%2.02%10/16/2025 (Estimated)VIEViela Bio-$86.43M-$7.02N/AN/AN/AN/A-33.97%-31.49%N/ALatest ADV, SANT, MAN, and VIE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ADVAdvantage Solutions$0.12N/AN/AN/A$792.51 millionN/A7/17/2025Q2 2025MANManpowerGroup$0.69$0.78+$0.09-$1.44$4.34 billion$4.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVAdvantage SolutionsN/AN/AN/AN/AN/AMANManpowerGroup$1.443.67%N/AN/A N/AVIEViela BioN/AN/AN/AN/AN/ALatest ADV, SANT, MAN, and VIE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025MANManpowerGroupsemi-annual$0.723.5%6/2/20256/2/20256/16/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVAdvantage Solutions2.391.991.99MANManpowerGroup0.240.981.12VIEViela BioN/A19.5119.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVAdvantage Solutions49.82%MANManpowerGroup98.03%VIEViela Bio46.98%Insider OwnershipCompanyInsider OwnershipADVAdvantage Solutions6.20%MANManpowerGroup3.10%VIEViela Bio31.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVAdvantage Solutions69,000324.31 million304.21 millionOptionableMANManpowerGroup26,70046.28 million44.85 millionOptionableVIEViela Bio16654.95 millionN/ANot OptionableADV, SANT, MAN, and VIE HeadlinesRecent News About These CompaniesBETDAQ app downloadDecember 30, 2024 | bwsmartcities.businessworld.inBdc vs punjab 2022December 30, 2024 | everythingexperiential.businessworld.inEKhelo India Khelo lucky 3 result todayDecember 30, 2024 | bweducation.businessworld.inB777 Win SooterDecember 30, 2024 | bwdisrupt.businessworld.inBTherapeutic Drug Monitoring in Rheumatology Has Potential but Faces a Host of HurdlesOctober 23, 2024 | medscape.comMAnti-CD19 Monoclonal Antibody Shows Positive Results in Myasthenia GravisOctober 16, 2024 | msn.comDmitry Bivol: Biography, record, fights and moreOctober 10, 2024 | espn.comRGNX-Aktie erreicht 52-Wochen-Tief bei 9,28 US-DollarOctober 9, 2024 | de.investing.comRoche takes on Alexion as FDA approves satralizumab in NMOSDSeptember 29, 2024 | pharmaphorum.comPREGENXBIO Inc.: REGENXBIO Appoints Mitchell Chan as Chief Financial OfficerSeptember 17, 2024 | finanznachrichten.deREGENXBIO ernennt Mitchell Chan zum neuen CFO in WachstumsphaseSeptember 17, 2024 | de.investing.comRegenxbio Names Mitchell Chan CFOSeptember 17, 2024 | markets.businessinsider.comAstraZeneca spins out biotech to focus on autoimmune candidatesAugust 27, 2024 | pharmaphorum.comPComplement Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020-2034) | DelveInsightAugust 21, 2024 | prnewswire.co.ukPMinority Stockholder Was Not a Controller Because Plaintiff Did Not Adequately Plead Actual Control of the Company’s Business AffairsAugust 21, 2024 | law.comLFactor D Complement Inhibitor Market Will Witness Robust Growth with Emerging Therapies by 2034 | DelveInsightAugust 19, 2024 | finance.yahoo.comLitigation Leaders: Adam Siegel of Freshfields on Four ‘Cs’ of the Firm’s Litigation PracticeAugust 19, 2024 | law.comL2024 Fire Awards: Meet this year's Ablaze honoreesAugust 16, 2024 | bizjournals.comAmgen Touts Q2 Growth Bolstered by Horizon Buy, Promising Obesity PipelineAugust 8, 2024 | biospace.comBNovel Drug Made of Gold Nanocrystals Appears Safe in Multiple SclerosisApril 22, 2024 | medpagetoday.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffSoundHound Rises as Short Sellers Exit and AI Demand GrowsBy Thomas Hughes | July 9, 2025View SoundHound Rises as Short Sellers Exit and AI Demand GrowsTesla: 2 Plays Ahead of Next Week's Earnings ReportBy Sam Quirke | July 15, 2025View Tesla: 2 Plays Ahead of Next Week's Earnings Report3 Stocks Poised to Benefit From the "Big Beautiful Bill"By Nathan Reiff | July 7, 2025View 3 Stocks Poised to Benefit From the "Big Beautiful Bill"Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 OutlookBy Brian O'Connell | July 15, 2025View Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 OutlookADV, SANT, MAN, and VIE Company DescriptionsAdvantage Solutions NASDAQ:ADV$1.30 -0.07 (-5.11%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.30 -0.01 (-0.38%) As of 08/1/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Advantage Solutions Inc. provides business solutions to consumer goods manufacturers and retailers in North America and internationally. It operates in two segments, Sales and Marketing. The Sales segment offers brand-centric services, such as headquarter relationship management; analytics, insights, and intelligence; and brand-centric merchandising services. This segment also provides retailer-centric services comprising retailer-centric merchandising and in-store media services. The Marketing segment offers brand-centric services, including shopper and consumer marketing, and brand experiential services; retailer-centric services, such as retail experiential and private label services; and digital marketing, and digital media and advertising services. The company was formerly known as Karman Holding Corp. and changed its name to Advantage Solutions Inc. in March 2016. The company was founded in 1987 and is headquartered in Irvine, California.ManpowerGroup NYSE:MAN$39.25 -2.00 (-4.84%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$39.24 -0.01 (-0.04%) As of 08/1/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ManpowerGroup Inc. provides workforce solutions and services worldwide. The company offers recruitment services, including permanent, temporary, and contract recruitment of professionals, as well as administrative and industrial positions under the Manpower and Experis brands. It also offers various assessment services; training and development services; career and talent management; and outsourcing services related to human resources functions primarily in the areas of large-scale recruiting and workforce-intensive initiatives. In addition, the company provides workforce consulting services; contingent staffing and permanent recruitment services; professional resourcing and project-based services; and recruitment process outsourcing, TAPFIN managed, and talent solutions. The company was incorporated in 1948 and is headquartered in Milwaukee, Wisconsin.Viela Bio NASDAQ:VIEViela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
